You are here

Cover Story

Cost Implications of Using Unfractionated Heparin or Enoxaparin in Medical Patients at Risk for Venous Thromboembolic Events

Richard M. Weinberg, MD, CPE, Leo K. Lichtig, PhD, Joseph A. Caprini, MD, MS, Geno J. Merli, MD, and F. Randy Vogenberg, RPh, PhD
PDF version: 
Using “real-world” data, the authors present a comparison of costs of unfractionated heparin and a low-molecular-weight heparin (enoxaparin) in preventing thromboembolism in hospitalized patients.